NCT00312052View on ClinicalTrials.gov

Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

720

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

August 31, 2009

Conditions
Coronary Artery Disease
Interventions
DRUG

E5555

50 mg or 100 mg E5555 tablets

DRUG

Placebo

50 mg and/or 100 mg placebo tablets

Trial Locations (2)

32605

Florida Research Network, Gainesville

49707

Great Lakes Heart Center of Alpena, Alpena

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT00312052 - Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease | Biotech Hunter | Biotech Hunter